Real‐life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)

Abstract

BACKGROUND:This study aimed to describe the treatment strategies and outcomes for women with newly diagnosed advanced highgrade serous or endometrioid ovarian cancer (OC). METHODS: This observational study collected real-world medical record data from eight Western countries on the diagnostic workup, clinical outcomes, and treatment of adult women with newly diagnosed advanced (Stage III-IV) high-grade serous or endometrioid OC. Patients were selected backward in time from April 1, 2018 (the index date), with a target of 120 patients set per country, followed for ≥20 months. RESULTS: Of the 1119 women included, 66.9% had Stage III disease, 11.7% had a deleterious BRCA mutation, and 26.6% received bevacizumab; 40.8% and 39.3% underwent primary debulking surgery (PDS) and interval debulking surgery (IDS), respectively. Of the patients who underwent PDS, 55.5% had no visible residual disease (VRD); 63.9% of the IDS patients had no VRD. According to physician-assessed responses (at the first assessment after diagnosis and treatment), 53.2% of the total population had a complete response and 25.7% had a partial response to first-line chemotherapy after surgery. After ≥20 months of follow-up, 32.9% of the patients were disease-free, 46.4% had progressive disease, and 20.6% had died. Bevacizumab use had a significant positive effect on overall survival (hazard ratio [HR], 0.62; 95% CI, 0.42-0.91; p = .01). A deleterious BRCA status had a significant positive effect on progression-free survival (HR, 0.60; 95% CI, 0.41-0.84; p < .01). CONCLUSIONS: Women with advanced high-grade serous or endometrioid OC have a poor prognosis. Bevacizumab use and a deleterious BRCA status were found to improve survival in this real-world population. Cancer 2022;128:3080-3089.

Ovarian Cancer in the Older Manitoban Population—Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study

“…The low numbers of patients receiving standard of care therapy and the high percentage of dose reduction or early dose interruption is in contrast with younger epithelial ovarian cancer patients. Treatment efficacy rates and survival percentages are modeled off clinical trials comprised primarily of patients under the age of 75, with high treatment completion rates and low–moderate dose reduction rates [ 12 ]. This emphasizes that patient selection for treatment is clinically very challenging and is an area where improvement and ongoing research are required.…”

Unveiling the Promise: A Comprehensive Review of Salpingectomy as a Vanguard for Ovarian Cancer Prevention

“…The RESPONSE trial is an observational, multinational cohort study that collected real-world medical record data from eight Western countries on the diagnostic workup, clinical outcomes, and treatment strategies for women with newly diagnosed advanced high-grade serous or endometrioid ovarian cancer [ 22 ]. A clinical trial at the Mayo Clinic aims to identify candidate biomarkers for early detection and chemotherapy treatment response in high-grade serous cancer (HGSC) [ 23 ].…”

“…Furthermore, the RESPONSE trial, an observational, multinational cohort study, aimed to describe the treatment strategies and outcomes for women with newly diagnosed advanced high‐grade serous or endometrioid ovarian cancer. The study collected real-world medical record data on the diagnostic workup, clinical outcomes, and treatment strategies for ovarian cancer from eight Western countries [ 22 ]. In addition, a clinical trial at the Mayo Clinic aims to identify candidate biomarkers for early detection and chemotherapy treatment response in HGSC.…”

The G-Protein-Coupled Estrogen Receptor Selective Agonist G-1 Attenuates Cell Viability and Migration in High-Grade Serous Ovarian Cancer Cell Lines

“…The most lethal gynecologic carcinoma is ovarian cancer. This cancer has a 5-year survival rate of ~45%, making it the fourth most common cancer with regards to mortality among Western nations [1][2][3]. The identification of molecular targets could aid in developing pharmacologic therapies to improve the prognosis for ovarian cancer [4].…”

“…Selective GPER agonists and antagonists have recently been discovered to differentiate GPER-mediated estrogen activity from that of ER [10][11][12] . Consequently, G-1 1-[4-(6-bromobenzo [1,3]dioxol-5yl)-3A, 4,5, 9B, tetrahydro-3H cyclopenta[c] quinolin-8-yl]-ethanone has been recently demonstrated to be a GPER agonist [10]. Previous studies have shown that G-1 is a high-affinity, nonsteroidal, and selective GPER agonist [10,11].…”